Loading organizations...
Based in South San Francisco, California, 3T Biosciences is a clinical-stage biotechnology company that develops next-generation immunotherapy treatments for solid tumors by utilizing a proprietary machine learning platform to identify novel T-cell receptor targets. The organization exclusively licensed a genetic-engineering discovery platform from Stanford University to modify T-cells and create therapies that direct the human immune system to attack specific cancer cells. Operating as a privately held venture-backed startup, the enterprise emerged from stealth mode after raising $40 million in Series A financing from lead investors including Westlake Village BioPartners, Lightspeed Venture Partners, and Thiel Capital. Furthermore, the firm secured a strategic research and licensing partnership with pharmaceutical manufacturer Boehringer Ingelheim that includes upfront compensation and potential milestone payments totaling up to $268 million. 3T Biosciences was founded in 2017 by researchers Leah Sibener, Luke Lee, Gee Marvin, and K. Christopher Garcia.
3T Biosciences has raised $52.0M across 2 funding rounds.
3T Biosciences has raised $52.0M in total across 2 funding rounds.
3T Biosciences has raised $52.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 3, 2022 | $40M Series A | Sean E. Harper | Lightspeed Venture Partners | Announced |
| Oct 1, 2017 | $12M Seed | Peter Thiel, Sean Parker | Menlo Ventures, Operator Collective | Announced |
3T Biosciences has raised $52.0M in total across 2 funding rounds.
3T Biosciences's investors include Sean E. Harper, Lightspeed Venture Partners, Peter Thiel, Sean Parker, Menlo Ventures, Operator Collective.
3T Biosciences is a biotechnology company developing next-generation T-cell receptor (TCR)-based immunotherapies for solid tumors and immune-mediated diseases.[1][2][4][5] It builds proprietary platforms like 3T-TRACE™ and 3T-PRIME™ to discover and validate TCR targets using immune-response-guided approaches, machine learning, and diverse target libraries, aiming for safer, more effective therapies in broad patient populations.[1][3][5] The company serves the oncology and immunotherapy sectors, addressing challenges in treating difficult cancers by enabling the immune system to target and destroy cancer cells.[1][2][4] Its lead program, 3T-403 (a pHLA/CD3 bispecific), is in IND-enabling studies and slated for clinical trials in solid tumors in early 2026, signaling strong growth momentum backed by investors like Westlake Village BioPartners, Lightspeed Venture Partners, and the Parker Institute for Cancer Immunotherapy.[1][2][3]
3T Biosciences was founded in 2017 in South San Francisco, California, emerging from research in Dr. K. Christopher Garcia's lab at Stanford University.[1][5] The company's platforms stem from breakthroughs in TCR biology, immunology, structural biology, protein engineering, bioinformatics, and machine learning, with key leaders like the Chief Scientific Officer driving development of 3T-TRACE™ and 3T-PRIME™.[1] Early traction came from assembling an experienced team, including executives from Turnstone Biologics, PACT Pharma, Five Prime Therapeutics, and Bavarian Nordic, who advanced preclinical TCR therapies for solid tumors.[1] Pivotal moments include securing top-tier funding and filing 10 patents focused on immune system topics like clusters of differentiation and immunology, positioning 3T for rapid pipeline progression.[1]
3T Biosciences rides the TCR immunotherapy wave, a key trend in oncology where harnessing T-cells promises curative potential for solid tumors unresponsive to checkpoint inhibitors or CAR-T therapies.[1][2][4][5] Timing is ideal amid surging demand for precision immune therapies, fueled by advances in AI-driven discovery and structural biology, which 3T pioneered from Stanford roots.[5] Market forces like rising cancer incidence, regulatory support for bispecifics, and investor enthusiasm for biotech (evident in 3T's backers) favor expansion.[1][3] 3T influences the ecosystem by validating new TCR targets, partnering for broader applications, and contributing publications/patents that advance immunotherapy standards.[1][4]
3T Biosciences is poised for clinical breakthroughs, with 3T-403 entering trials in early 2026 and additional TCR programs advancing via 3T-TRACE™.[2] Trends like AI integration in drug discovery and multimodal immune therapies will accelerate its pipeline, potentially yielding first-in-class solid tumor treatments.[1][3][5] Influence may grow through partnerships, expanded indications beyond oncology, and scaling its platforms for immune-mediated diseases, solidifying 3T as a leader in transformative TCR therapeutics.[4] This positions the immunotherapy pioneer—from Stanford innovation to clinic-ready assets—at the forefront of cancer's next treatment frontier.[1][5]
